TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Continued supply of medicines to patients in the UK post-Brexit

Continued supply of medicines to patients in the UK post-Brexit

Brexit or no Brexit, deal or no-deal, patients in the UK and the EU will continue to need treatment for all conditions after the 29th of March 2019. In the event of a no-deal Brexit, UK Marketing Authorisation Holders (MAHs) will need to ensure continued authorisation and, hence, supply of medicines in the UK. In an effort to reduce the risk of product shortages in this scenario, the UK government has drafted legislation whereby Centrally Authorisation Product (CAP) Marketing Authorisations (MAs) will automatically convert to UK MAs in a process known as ‘grand-fathering’1. Product Licence (PL) numbers will also be issued to CAPs by the MHRA based on current UK practice2. To facilitate this transition, the Medicine & Healthcare Products Regulatory Agency (MHRA) in the UK has issued guidance detailing the proposed baseline data which will be required to be submitted in the form of an initiating electronic Common Technical Document (eCTD) sequence between 29th March 2019 and 29th March 2020.

Briefly, the data submission package must contain1:

  1. A cover letter and declaration that the documentation included in the package is approved.
  2. A single eCTD initiating sequence for the converted EU MA indicating the current authorised and approved position of the product.
  3. An electronic application form (eAF) for each converted EU MA.
  4. A complete summary of the historical regulatory activity associated with the CAP including: the type of submission; date of submission to the EMA; summary of submission; regulatory outcome; the date of the outcome and eCTD sequence number of the submission.
  5. Details regarding the current and previous marketing status of the converted EU MA on the UK market.
  6. The current EU approved Summary of Product Characteristics (SmPC).
  7. The current EU approved packaging and leaflets.

The eCTD must be technically valid, and the data submitted must be relevant to the UK market1.

More information regarding the method of submission, which is expected to be via a newly developed portal, and the preparation of an initiating sequence can be found in a document issued by the MHRA entitled Guidance on Converting Centrally Authorised Products (CAPs) to UK Marketing Authorisations (MAs) – proposed requirements for submitting baseline information.

MAHs can opt-out of converting some or all CAPs to UK MAs which would result in the products in question being unlicensed in the UK2. To do so, CAP MAHs should inform the MHRA by the end of January 2019 of any products that they do not wish to convert to UK MAs2.

You can find all of the latest news and documents issued by the MHRA at the link below:

https://www.gov.uk/government/latest?departments%5B%5D=medicines-and-healthcare-products-regulatory-agency

If you wish to discuss how PharmaLex can support your organisation during the transition period when the UK exit the EU, please connect with us at +353 1 846 4742 or contactirl@pharmalex.com.

 

References

  1. Medicine & Healthcare Products Regulatory Agency. Guidance on Converting Centrally Authorised Products (CAPs) to UK Marketing Authorisations (MAs) –proposed requirements for submitting baseline information. 26th November 2018.
  2. Medicine & Healthcare Products Regulatory Agency. Preparations in the event of a No-deal Brexit Preparation: Conversion of Centrally Authorised Products (CAPs) to UK Marketing Authorisations (MAs). 26th November 2016.
Related posts
Why collaboration and an Integrated Product Development program are key to successful drug development
Why collaboration and an Integrated Product Development program are key to successful drug development
14th June 2022
Key Takeaways from the PDA Europe Annex 1 Workshop
Key Takeaways from the PDA Europe Annex 1 Workshop
7th June 2022
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Search
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • I just wanted to relay our sincere thanks to you and the team for two really excellent days training. It was well organized and structured to cover regulatory expectations, GMP principle and routine work challenges of industry. The presenters and moderator were highly skilled in this area to accommodate any queries raised during the training session and were well able to keep the team engaged even in remote/virtual training session. The design of training slides was impressive and the use of technology to make virtual training was remarkable.

    Lorraine Henry
    Compliance Lead, Qualified Person, Amneal Ireland Limited
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for